Overview

This trial is active, not recruiting.

Conditions adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1, untreated adult acute lymphoblastic leukemia
Treatments alemtuzumab, allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, cyclophosphamide, cytarabine, dasatinib, daunorubicin hydrochloride, dexamethasone, etoposide phosphate, filgrastim, fludarabine phosphate, in vitro-treated peripheral blood stem cell transplantation, laboratory biomarker analysis, leucovorin calcium, melphalan, mercaptopurine, methotrexate, pegfilgrastim, pharmacological study, tacrolimus, vincristine sulfate
Phase phase 2
Targets BCR-ABL, CD52
Sponsor National Cancer Institute (NCI)
Start date December 2010
End date February 2018
Trial size 66 participants
Trial identifier NCT01256398, CALGB 10701/CTSU C10701, CALGB-10701, CDR0000690286, NCI-2011-02621, U10CA031946, U10CA180821

Summary

This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
See Detailed Description
alemtuzumab Anti-CD52 Monoclonal Antibody
Given IV
allogeneic hematopoietic stem cell transplantation allogeneic stem cell transplantation
Undergo peripheral blood allogeneic HCT
autologous hematopoietic stem cell transplantation Autologous Stem Cell Transplantation
Undergo peripheral blood autologous HCT
cyclophosphamide (-)-Cyclophosphamide
Given IV
cytarabine .beta.-Cytosine arabinoside
Given IV
dasatinib BMS-354825
Given PO
daunorubicin hydrochloride Cerubidin
Given IV
dexamethasone Aacidexam
Given PO or IV
etoposide phosphate Etopophos
Given IV
filgrastim Filgrastim XM02
Given SC
fludarabine phosphate 2-F-ara-AMP
Given IV
in vitro-treated peripheral blood stem cell transplantation in vitro-treated PBPC transplantation
Undergo peripheral blood autologous or allogeneic HCT
laboratory biomarker analysis
Correlative studies
leucovorin calcium Adinepar
Given IV or PO
melphalan Alanine Nitrogen Mustard
Given IV
mercaptopurine 3H-Purine-6-thiol
Given PO
methotrexate Abitrexate
Given IT, IV, or PO
pegfilgrastim Filgrastim SD-01
Given SC
pharmacological study
Correlative studies
tacrolimus FK 506
Given IV or PO
vincristine sulfate Kyocristine
Given IV

Primary Outcomes

Measure
DFS defined from the date of first induction complete response (CR) to relapse or death due to any cause
time frame: At 3 years

Secondary Outcomes

Measure
DFS
time frame: From the date of first induction CR to relapse, or death due to any cause, with patients last known to be alive and disease-free censored at the date of last contact, assessed up to 10 years
Feasibility of maintenance therapy in this patient population (restricted to those patients achieving a CR)
time frame: Up to 10 years
OS
time frame: Up to 10 years
Probability of being BCR-ABL negative in the bone marrow and peripheral blood at the completion of the CNS prophylaxis course (restricted to those patients achieving a CR)
time frame: Up to 10 years
Response
time frame: Up to 10 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Unequivocal histologic diagnosis of ALL - Detection of the t(9;22)(q34;q11) or 3-way variant by metaphase cytogenetics or BCR-ABL positive status by molecular analysis (Q-PCR or fluorescent in situ hybridization [FISH]) in a Cruise Lines International Association (CLIA)-approved laboratory - No prior therapy except up to one week of corticosteroids and/or hydroxyurea to enable time for the detection of t(9;22)(q34;q11) or BCR/ABL - Non-pregnant and non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control and contraception should continue for three months after the last dose of dasatinib to allow complete clearance of drug and its principal metabolites from the body; in women of childbearing potential, a pregnancy test will be required at study entry - Left ventricular ejection fraction >= lower limit of institutional normal - No myocardial infarction within 6 months - No ventricular tachyarrhythmia within 6 months - No major conduction abnormality (unless a cardiac pacemaker is present)

Additional Information

Official title A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
Principal investigator Matthew Wieduwilt
Description PRIMARY OBJECTIVES: I. Estimate the disease-free survival (DFS) and overall survival (OS) profiles in newly diagnosed patients 18 years or older who have Philadelphia chromosome positive (Ph+) (BCR/(v-abl Abelson murine leukemia viral oncogene homolog [ABL]+) acute lymphoblastic leukemia (ALL) receiving sequential dasatinib followed by allogeneic or autologous hematopoietic cell transplant (HCT) or chemotherapy followed by dasatinib maintenance. SECONDARY OBJECTIVES: I. Compare the OS and DFS profiles for each of the three cohorts to those from similar populations from other studies. II. Determine the ability of dasatinib to produce or maintain a BCR/ABL-negative status, as judged by quantitative-polymerase chain reaction (Q-PCR) following sequential dasatinib, chemotherapy, and HCT. III. Determine the feasibility of collecting adequate peripheral blood stem cells for autologous HCT following dasatinib therapy and assess for residual Ph+ (BCR/ABL+) cells by Q-PCR. IV. Study the safety and efficacy of autologous HCT following therapy with dasatinib. V. Study the safety and efficacy of reduced-intensity preparatory regimen followed by an allogeneic HCT following induction therapy with dasatinib. VI. Study the safety and efficacy of dasatinib maintenance administered after allogeneic or autologous HCT or chemotherapy. VII. Correlate plasma and cerebrospinal fluid (CSF) levels of dasatinib when given orally during induction. OUTLINE: As of 8/21/2014, no new patients may be enrolled on E3903. REMISSION INDUCTION THERAPY (RIT): Patients receive dasatinib orally (PO) daily continuously and dexamethasone PO or intravenously (IV) on days 1-7. EARLY INTENSIFICATION THERAPY: Patients with bone marrow =< 20% blasts are assigned to cohort A and patients with bone marrow > 20% blasts are assigned to cohort B. COHORT A: Patients receive dasatinib and dexamethasone as in RIT. COHORT B: Patients receive dasatinib and dexamethasone as in RIT, and vincristine sulfate IV and daunorubicin hydrochloride IV on days 1, 8, and 15. Patients who do NOT achieve a complete response (CR) or CR with incomplete hematologic recovery based on bone marrow continue on to second induction therapy; patients who achieve a hematologic and morphologic CR continue on to CNS prophylaxis therapy. SECOND INDUCTION THERAPY: Patients receive dasatinib and dexamethasone as in RIT, cyclophosphamide IV on day 1, daunorubicin hydrochloride IV and vincristine sulfate IV on days 1 and 8, and filgrastim subcutaneously (SC) beginning on day 9 and continuing for >= 7 days or one dose of pegfilgrastim on day 9. CNS PROPHYLAXIS THERAPY: Patients receive dasatinib PO daily continuously during CNS prophylaxis therapy; methotrexate intrathecally (IT), vincristine sulfate IV, and methotrexate IV over 3 hours on days 1, 15, and 29; methotrexate PO every 6 hours for a total of 4 doses each on days 1-2, 15-16, and 29-30; leucovorin calcium IV on days 2, 16, and 30; and leucovorin PO calcium every 6 hours for a total of 8 doses each on days 3-4, 17-18, and 31-32. TRANSPLANTATION OR ALTERNATIVE CHEMOTHERAPY AND MAINTENANCE THERAPY: Patients aged 50-70 years with an HLA-matched related or unrelated donor are assigned to allogeneic transplantation, patients aged 50-70 years without an HLA-matched related or unrelated donor are assigned to autologous transplantation, and patients aged > 70 years or who are not transplantation candidates are assigned to alternative chemotherapy. ALLOGENEIC TRANSPLANTATION: Patients receive fludarabine phosphate IV over 30 minutes and alemtuzumab IV over 30 minutes on days -7 through -3 and melphalan IV over 30 minutes on day -2. Patients undergo allogeneic peripheral blood stem cell transplantation (PBSCT) on day 0. Patients then receive filgrastim SC beginning on day 1 and continuing until count recovery and tacrolimus IV or PO beginning on day -2 and beginning to taper on day 100 (for matched related donors) or day 180 (for mismatched related or unrelated donors). Beginning on day 30, patients receive dasatinib PO daily as maintenance therapy. Treatment continues for >= 12 months in the absence of disease progression. AUTOLOGOUS TRANSPLANTATION: MOBILIZATION: Patients receive etoposide phosphate IV continuously on days 1-4, high-dose cytarabine IV over 2 hours every 12 hours for a total of 8 doses on days 1-4, and filgrastim SC once or twice daily beginning on day 14 and continuing until peripheral blood stem cell collection is complete or WBC > 50,000/μL. LEUKAPHERESIS: Patients undergo leukapheresis beginning when WBC > 10,000/μL for a target collection of >= 5 x 10^6 CD34+ cells/kg. After completion of stem cell collection, patients receive dasatinib PO twice daily until 3 days before transplantation. TRANSPLANTATION: Beginning >= 4 weeks after recovery from toxicity related to previous treatment, patients receive melphalan IV over 30 minutes on days -2 and -1. Patients undergo autologous PBSCT on day 0. Patients then receive filgrastim SC beginning on day 0 and continuing until count recovery. MAINTENANCE THERAPY: Beginning on day 30, patients receive dasatinib PO once daily. Treatment continues for >= 12 months in the absence of disease progression. ALTERNATIVE CHEMOTHERAPY: Beginning 3-10 days after completion of CNS prophylaxis therapy, patients receive etoposide phosphate IV continuously on days 1-4, high-dose cytarabine IV over 2 hours every 12 hours for a total of 8 doses on days 1-4, and filgrastim SC once or twice daily beginning on day 14 and continuing until count recovery. MAINTENANCE THERAPY: Patients receive dasatinib PO once daily beginning on day 30. Patients also receive vincristine sulfate IV every 4 weeks, dexamethasone for 5 days every 4 weeks, mercaptopurine PO once daily, and methotrexate PO once weekly. Treatment continues for >= 12 months in the absence of disease progression. NOTE: Patients with CNS leukemia or testicular disease may receive additional treatment. After completion of study treatment, patients are followed up every month for 1 year, every 3 months for 2 years, every 6 months for 2 years, and every year for 5 years.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).